Location of Repository

Deregulated MicroRNAs in Myotonic Dystrophy Type 2

By Simona Greco, Alessandra Perfetti, Pasquale Fasanaro, Rosanna Cardani, Maurizio C. Capogrossi, Giovanni Meola and Fabio Martelli


Myotonic Dystrophy Type-2 (DM2) is an autosomal dominant disease caused by the expansion of a CCTG tetraplet repeat. It is a multisystemic disorder, affecting skeletal muscles, the heart, the eye, the central nervous system and the endocrine system. Since microRNA (miRNA) expression is disrupted in Myotonic Dystrophy Type-1 and many other myopathies, miRNAs deregulation was studied in skeletal muscle biopsies of 13 DM2 patients and 13 controls. Eleven miRNAs were deregulated: 9 displayed higher levels compared to controls (miR-34a-5p, miR-34b-3p, miR-34c-5p, miR-146b-5p, miR-208a, miR-221-3p and miR-381), while 4 were decreased (miR-125b-5p, miR-193a-3p, miR-193b-3p and miR-378a-3p). To explore the relevance of DM2 miRNA deregulation, the predicted interactions between miRNA and mRNA were investigated. Global gene expression was analyzed in DM2 and controls and bioinformatic analysis identified more than 1,000 miRNA/mRNA interactions. Pathway and function analysis highlighted the involvement of the miRNA-deregulated mRNAs in multiple aspects of DM2 pathophysiology. In conclusion, the observed miRNA dysregulations may contribute to DM2 pathogenetic mechanisms

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3387258
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2009). A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance.
    2. (2009). A novel and universal method for microRNA RT-qPCR data normalization.
    3. (1998). Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin.
    4. (1992). An unstable triplet repeat in a gene related to myotonic muscular dystrophy.
    5. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408. microRNAs Expression
    6. (1993). Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis.
    7. (2004). Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy.
    8. (2011). Cellular toxicity of expanded RNA repeats: focus on RNA foci.
    9. (1995). Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene.
    10. (2009). Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia.
    11. (2010). Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2.
    12. (2009). differentiation and maturation of skeletal muscle cells.
    13. (2009). Distinct actions of Akt1 and Akt2 in skeletal muscle differentiation.
    14. (2007). Distinctive patterns of microRNA expression in primary muscular disorders.
    15. (2011). Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1.
    16. (2009). Evidence of MyomiR network regulation of beta-myosin heavy chain gene expression during skeletal muscle atrophy.
    17. (2007). Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2.
    18. (2003). Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2.
    19. (2011). IGF-II is regulated by microRNA-125b in skeletal myogenesis.
    20. (2001). In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts.
    21. (2009). Mechanisms of miRNA-mediated posttranscriptional regulation in animal cells.
    22. (2012). MicroRNA Dysregulation in Diabetic Ischemic Heart Failure Patients.
    23. (2011). MicroRNA history: discovery, recent applications, and next frontiers.
    24. (2010). microRNA: emerging therapeutic targets in acute ischemic diseases.
    25. (2011). MicroRNAs in skeletal myogenesis.
    26. (2010). MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway.
    27. (2005). MicroRNAs: critical regulators of development, cellular physiology and malignancy.
    28. (2009). MicroRNAs: target recognition and regulatory functions.
    29. (2011). miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy.
    30. (2010). MiRonTop: mining microRNAs targets across large scale gene expression studies.
    31. (2011). Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy.
    32. (1992). Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 39 end of a transcript encoding a protein kinase family member.
    33. (2004). Muscle pathology in 57 patients with myotonic dystrophy type 2.
    34. (2001). Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.
    35. (1992). Myotonic dystrophy mutation: an unstable CTG repeat in the 39 untranslated region of the gene.
    36. (2011). Myotonic dystrophy type 2 (DM2) and related disorders report
    37. (2001). Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.
    38. (2003). Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.
    39. (2009). Myotonic dystrophy.
    40. (2012). Novel insights into the pathomechanisms of skeletal muscle channelopathies.
    41. (2010). Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients.
    42. (2005). Oxidative stress in myotonic dystrophy type 1. Free Radic
    43. (2010). Regulation and dysregulation of fibrosis in skeletal muscle.
    44. (2006). The diverse functions of microRNAs in animal development and disease.
    45. (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve.
    46. (2010). The miR-34 family in cancer and apoptosis.
    47. (2010). The myotonic dystrophies: diagnosis and management.
    48. (2010). The widespread regulation of microRNA biogenesis, function and decay.
    49. (2002). Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells.
    50. (2009). Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy.
    51. (1981). Use of relative operating characteristic analysis in epidemiology. A method for dealing with subjective judgement.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.